Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on January 15, 2004

Arteriosclerosis, Thrombosis, and Vascular Biology. 2004
Published online before print January 15, 2004, doi: 10.1161/01.ATV.0000117174.19078.85
A more recent version of this article appeared on March 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/3/564    most recent
01.ATV.0000117174.19078.85v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flood, C.
Right arrow Articles by Borén, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flood, C.
Right arrow Articles by Borén, J.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
*Genetics Home Reference
Related Collections
Right arrow Animal models of human disease
Right arrow Cell biology/structural biology
Right arrow Genetically altered mice
Right arrow Lipid and lipoprotein metabolism

Submitted on July 3, 2003
Accepted on December 1, 2003

Molecular Mechanism for Changes in Proteoglycan Binding on Compositional Changes of the Core and the Surface of Low-Density Lipoprotein-Containing Human Apolipoprotein B100

Christofer Flood ; Maria Gustafsson ; Robert E. Pitas ; Lorenzo Arnaboldi ; Rosemary L. Walzem ; and Jan Borén *

From the Wallenberg Laboratory for Cardiovascular Research (C.F., M.G., J.B.), The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden; the Gladstone Institute of Cardiovascular Disease (R.E.P., L.A.), Cardiovascular Research Institute and the Department of Pathology (R.E.P.), University of California, San Francisco; and the Department of Poultry Science (R.L.W.), Texas A&M University, Kleberg Center, College Station, TX.

* To whom correspondence should be addressed. E-mail: Jan.Boren{at}wlab.gu.se.

Objective--The aim of this study was to investigate the molecular mechanism for changes in proteoglycan binding and LDL receptor affinity on two compositional changes in LDL that have been associated with atherosclerosis: cholesterol enrichment of the core and modification by secretory group IIA phospholipase A2 (sPLA2) of the surface.

Methods and Results--Transgenic mice expressing recombinant apolipoprotein (apo) B and sPLA2 were generated. Recombinant LDL were isolated and tested for their proteoglycan and LDL receptor-binding activity. The results show site A (residues 3148 to 3158) in apoB100 becomes functional in sPLA2-modified LDL and that site A acts cooperatively with site B (residues 3359 to 3369), the primary proteoglycan-binding site in native LDL, in the binding of sPLA2-modified LDL to proteoglycans. Our results also show that cholesterol enrichment of LDL is associated with increased affinity for proteoglycans and for the LDL receptor. This mechanism is likely mediated by a conformational change of site B and is independent of site A in apoB100.

Conclusion--Site A in apoB100 becomes functional in sPLA2-modified LDL and acts cooperatively with site B resulting in increased proteoglycan-binding activity. The increased binding for proteoglycans of cholesterol-enriched LDL is solely dependent on site B.


Key words: lipoproteins • apolipoprotein B • proteoglycans • atherosclerosis • transgenic mice • phospholipase A2




This article has been cited by other articles:


Home page
DiabetesHome page
A. Hiukka, M. Stahlman, C. Pettersson, M. Levin, M. Adiels, S. Teneberg, E. S. Leinonen, L. M. Hulten, O. Wiklund, M. Oresic, et al.
ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan
Diabetes, September 1, 2009; 58(9): 2018 - 2026.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
B. B. Boyanovsky, P. Shridas, M. Simons, D. R. van der Westhuyzen, and N. R. Webb
Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL
J. Lipid Res., April 1, 2009; 50(4): 641 - 650.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. Boyanovsky, M. Zack, K. Forrest, and N. R. Webb
The Capacity of Group V sPLA2 to Increase Atherogenicity of ApoE-/- and LDLR-/- Mouse LDL In Vitro Predicts its Atherogenic Role In Vivo
Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 532 - 538.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. Bancells, S. Benitez, M. Jauhiainen, J. Ordonez-Llanos, P. T. Kovanen, S. Villegas, J. L. Sanchez-Quesada, and K. Oorni
High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level
J. Lipid Res., March 1, 2009; 50(3): 446 - 455.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. Divchev, C. Grothusen, M. Luchtefeld, M. Thoenes, F. Onono, R. Koch, H. Drexler, and B. Schieffer
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease
Eur. Heart J., August 2, 2008; 29(16): 1956 - 1965.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. Tran-Lundmark, P.-K. Tran, G. Paulsson-Berne, V. Friden, R. Soininen, K. Tryggvason, T. N. Wight, M. G. Kinsella, J. Boren, and U. Hedin
Heparan Sulfate in Perlecan Promotes Mouse Atherosclerosis: Roles in Lipid Permeability, Lipid Retention, and Smooth Muscle Cell Proliferation
Circ. Res., July 3, 2008; 103(1): 43 - 52.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Tabas, K. J. Williams, and J. Boren
Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications
Circulation, October 16, 2007; 116(16): 1832 - 1844.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Gustafsson, M. Levin, K. Skalen, J. Perman, V. Friden, P. Jirholt, S.-O. Olofsson, S. Fazio, M. F. Linton, C. F. Semenkovich, et al.
Retention of Low-Density Lipoprotein in Atherosclerotic Lesions of the Mouse: Evidence for a Role of Lipoprotein Lipase
Circ. Res., October 12, 2007; 101(8): 777 - 783.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Oorni and P. T. Kovanen
PLA2-V: A Real Player in Atherogenesis
Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 445 - 447.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. Freeman, M. J. A. Amar, R. Shamburek, B. Paigen, H. B. Brewer Jr., S. Santamarina-Fojo, and H. Gonzalez-Navarro
Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice
J. Lipid Res., January 1, 2007; 48(1): 104 - 113.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S.-A. Karabina, I. Brocheriou, G. Le Naour, M. Agrapart, H. Durand, M. Gelb, G. Lambeau, and E. Ninio
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function
FASEB J, December 1, 2006; 20(14): 2547 - 2549.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. W. Joyce, E. M. Wagner, F. Basso, M. J. Amar, L. A. Freeman, R. D. Shamburek, C. L. Knapper, J. Syed, J. Wu, B. L. Vaisman, et al.
ABCA1 Overexpression in the Liver of LDLr-KO Mice Leads to Accumulation of Pro-atherogenic Lipoproteins and Enhanced Atherosclerosis
J. Biol. Chem., November 3, 2006; 281(44): 33053 - 33065.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Namgaladze and B. Brune
Phospholipase A2-Modified Low-Density Lipoprotein Activates the Phosphatidylinositol 3-Kinase-Akt Pathway and Increases Cell Survival in Monocytic Cells
Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2510 - 2516.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Sneck, P. T. Kovanen, and K. Oorni
Decrease in pH Strongly Enhances Binding of Native, Proteolyzed, Lipolyzed, and Oxidized Low Density Lipoprotein Particles to Human Aortic Proteoglycans
J. Biol. Chem., November 11, 2005; 280(45): 37449 - 37454.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. B. Boyanovsky, D. R. van der Westhuyzen, and N. R. Webb
Group V Secretory Phospholipase A2-modified Low Density Lipoprotein Promotes Foam Cell Formation by a SR-A- and CD36-independent Process That Involves Cellular Proteoglycans
J. Biol. Chem., September 23, 2005; 280(38): 32746 - 32752.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. A. I. Ghesquiere, M. J. J. Gijbels, M. Anthonsen, P. J. J. van Gorp, I. van der Made, B. Johansen, M. H. Hofker, and M. P. J. de Winther
Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition
J. Lipid Res., February 1, 2005; 46(2): 201 - 210.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Gonzalez-Navarro, Z. Nong, M. J. A. Amar, R. D. Shamburek, J. Najib-Fruchart, B. J. Paigen, H. B. Brewer Jr., and S. Santamarina-Fojo
The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice
J. Biol. Chem., October 29, 2004; 279(44): 45312 - 45321.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J.-C. Hogue, B. Lamarche, D. Gaudet, M. Lariviere, A. J. Tremblay, J. Bergeron, I. Lemieux, J.-P. Despres, C. Gagne, and P. Couture
Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia
J. Lipid Res., June 1, 2004; 45(6): 1077 - 1083.
[Abstract] [Full Text] [PDF]